Answers are grounded in this paper and cite their sources.
A high risk of mycobacteriosis was noted in the population of patients with cystic fibrosis (CF). Lung damage caused by non-tuberculous mycobacteria (NTMB) can pose a serious health risk to patients with CF. They can cause lung damage leading to a rapid decrease in lung function and, under certain circumstances, death. The prevalence of NTMB among patients with CF varies widely from 1.3 to 32.7% in different regions of Europe and the USA, depending on the region and population characteristics. The Patient Registry of the Russian Federation notes a slight decrease in the number of patients infected with NTMB from 1.5% to 0.8%, however, the percentage of coverage of patients with mycobacteriosis studies is extremely small. The appearance of cftr modulators has radically changed the course of cystic fibrosis, however, there is currently insufficient data on their effect on the respiratory tract microbiome. The aim is to show the effect of cftr modulator therapy on the course of mycobacteriosis in adolescents with cystic fibrosis. The materials are case histories and outpatient card data of a patient being observed in the NIKI of childhood of the Ministry of Health of the Ministry of Defense. Results -describes the medical history of a teenager with cystic fibrosis, worsening of the condition (weakness, shortness of breath, increased cough, increased sputum, decreased FEV1 from 81% to 66% of normal, the appearance of new multiple foci on CT OGK). Mycobacteriosis was suspected, and the growth of mycobacterium abscessus was confirmed by a positive bacteriological analysis. Mycobacteriosis therapy has been initiated. During follow-up on the treatment of mycobacteriosis of the lungs (initiation phase intravenously for 4 weeks with imipen in combination with amikacin, oral administration of azithromycin 500 mg per day, and maintenance therapy - inhalation with amikacin 500 mg x 2 times a day, azithromycin 500 mg per day, courses of ciprofloxacin, linezolid, stabilization was achieved – not observed asthenic syndrome, respiratory syndrome, and a further decrease in spirometry. However, the spirometry indicators did not reach a normal level and remained below 80% of the required level. 5 months after the start of mycobacteriosis therapy, the child began receiving cftr modulator therapy – elecsacaftor 100mg+tezacaftor 50mg+ivacaftor 75mg 2 tablets in the morning and ivacaftor 150 mg 1 tablet in the evening (E). In control measurements, 3 months after the start of E therapy, an improvement in FEV1 spirometry was noted, increasing from 66% to 87%, which continued to improve as therapy with cftr modulators continued. There was a positive trend according to the control studies of multispiral computed tomography of the chest organs. Supportive antibacterial therapy was continued for 15 months, and no intravenous therapy was required. Further, maintenance therapy was gradually discontinued, completely 1.5 years after the start of therapy for mycobacteriosis of the lungs. At the age of 18, the young man was transferred to the adult cystic fibrosis center in the Moscow region. The child continues cftr modulator therapy. To date, the total course of targeted therapy has been more than 4 years. Conclusions : Each patient with a worsening condition in the absence of an effect from the therapy and excluding other causes of negative dynamics should be examined for mycobacteriosis. CFTR modulator therapy provides benefits to patients with cystic fibrosis and severe resistant bacterial pathogens in sputum.
No takes yet. Share an insight, caveat, or question.
Voronkova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: